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Objective. This study investigated the clinical significance of Shp2 protein expression in oral squamous cell carcinoma
(OSCC) and elucidated its biologic significance in OSCC cells.
Study Design. A total of 88 OSCC cases were used to assess Shp2 expression, out of which 70 were for immunohistochemistry
and 18 paired tumors vs normal tissues were for Western blot of Shp2 expression. OSCC cells were used to assess the effects of
Shp2 knockdown for cell viability, apoptosis, invasion, and protein expressions.
Results. Expression of Shp2 protein was significantly upregulated in OSCC tissues compared with the normal tissues, and
Shp2 overexpression was associated with advanced tumor clinical stages and lymph node metastasis ex vivo. Knockdown of
Shp2 expression in vitro inhibited OSCC cell viability and invasion but induced apoptosis by regulating expression of the
apoptosis-related proteins.
Conclusions. The data indicated that Shp2 may play an important role in OSCC progression. Further studies will investigate
whether a target of Shp2 expression could be a novel therapeutic strategy for clinical control of OSCC. (Oral Surg Oral Med
Oral Pathol Oral Radiol 2014;117:234-242)Head and neck squamous cell carcinoma (HNSCC) is a
devastating disease, although it accounts for only 3% of
all malignancies.1 HNSCC primarily affects the oral
cavity, hypopharynx, oropharynx, larynx, and salivary
glands, but more than 90% of HNSCCs are oral squa-
mous cell carcinoma (OSCC), which remains a lethal
disease in over 50% of the cases diagnosed annually2 and
affects the quality of life. In the clinic, because most
OSCCs are diagnosed at the advanced stage, treatment
fails, or patients develop a second primary cancer, local
recurrence, and distant metastasis.3 To date, treatment of
OSCC involves radical surgical resection with adjuvant
chemotherapy, radiotherapy, or both. However, in the
past 30 years, the long-term survival rate for OSCC has
not improved, and only 60% of OSCC patients survive
for 5 years.4,5 Thus, we should pay more attention to the
discovery of novel and effective treatment options to
improve the survival and quality of life of patients, in
addition to identifying novel biomarkers for early
detection and prediction of tumor progression.6-10
Cell activities, such as survival, proliferation, and
differentiation, are tightly controlled by intracellular
signaling initiated by extracellular factors, in which
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Open access under CC BY-NC-ND license.and dephosphorylation (conducted by protein phospha-
tases) play an important role.11 Src homology phospho-
tyrosyl phosphatase 2 (Shp2), encoded by the PTPN11
gene in humans, is a ubiquitously expressed protein
tyrosine phosphatase (PTP) with 2 N-terminal Src ho-
mology 2 (SH2) domains (N-SH2 and C-SH2, respec-
tively) and a catalytic (PTP) domain that acts as an
important transducer of the Ras-Erk pathway to promote
cell growth and production of cytokines and hormones.12
Depending on the speciﬁc cell type or receptor, Shp2
could also increase or decrease Rho activity,13 enhance
or antagonize PI3K-Akt activation,14 and possibly affect
the NFAT (nuclear factor of activated T cells) or NF-kB
(nuclear factor kappa B) pathways.15 Autosomal-domi-
nant mutations in human gene PTPN11 have been detec-
ted in nearly 50% of patients with Noonan syndrome
who have higher risk of suffering juvenile myelomono-
cytic leukemia.16 Somatic mutations constitutively acti-
vating Shp2 have also been detected in several types of
leukemia,17 and increased Shp2 expression has been re-
ported in different human cancers, including breast can-
cer,18 gastric cancer,19 cervical cancer,20 prostate cancer,21
melanoma,22 and thyroid cancer.23 These data suggest that
PTPN11 functions as a proto-oncogene.24Statement of Clinical Relevance
The study suggested that Shp2 should be further
evaluated as a novel biomarker for prediction of
OSCC progression and be further developed as a
therapeutic target for OSCC.
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other studies found that Shp2 may be a tumor sup-
pressor in hepatocellular carcinoma.25,26 These contra-
dictory results suggested that Shp2 may have dual roles
in tumorigenesis, and elucidating the functions of Shp2
could lead to better understanding of tyrosine phos-
phorylation in different cell contexts.
Furthermore, previous studies found that levels of
PTPN11 mRNA were signiﬁcantly higher in hypo-
pharyngeal SCC tissues compared with adjacent
noncancerous hypopharyngeal tissues, implicating
Shp2 involvement in OSCC.27 Thus, we initiated this
study by ﬁrst investigating the expression of Shp2
protein in OSCC tissues ex vivo and then knocking
down Shp2 expression in OSCC cells in vitro for
assessment of changed tumor cell viability, apoptosis,
invasion, and gene expression.MATERIALS AND METHODS
Tissue specimens
A total of 88 tissue specimens were used in the study, of
which 70 cases were retrospectively recruited for
immunohistochemical analysis of Shp2 expression. For
conﬁrmation of immunohistochemical data, we pro-
spectively recruited 18 paired tumors vs normal tissues
for Western blot assessment of Shp2 expression. Spe-
ciﬁcally, 70 tissue specimens were obtained from pa-
tients who underwent surgical resection of primary
OSCC in the Department of Oral and Maxillofacial
Surgery, The Provincial Hospital Afﬁliated to Shan-
dong University, between October 2008 and August
2011. These patients were not treated with any previous
radiotherapy or chemotherapy. Clinicopathologic data,
including gender, age, tumor (T) classiﬁcation, node
(N) classiﬁcation, metastasis (M) classiﬁcation, and
overall TNM stage were collected from medical records
and pathology reports. The TNM status was classiﬁed
according to the 2002 American Joint Committee on
Cancer Staging System.28 Parafﬁn-embedded speci-
mens of cancerous and normal tissues were retrieved
from pathology archives and sectioned for reevaluation
of pathologic diagnosis of OSCC and immunohisto-
chemical analysis of Shp2 expression.
In addition, 18 cases of fresh cancerous and normal
tissues were obtained from patients with OSCC at the
Department of Oral and Maxillofacial Surgery, The
Provincial Hospital Afﬁliated to Shandong University,
between January and April 2012. These samples were
histologically conﬁrmed by frozen sections to have
OSCC and were used for Western blot analysis of Shp2
expression. This study followed the Helsinki Declara-
tion and Guidelines and was approved by the Medical
Ethics and Human Clinical Trial Committee of The
Provincial Hospital Afﬁliated to Shandong University.All patients provided a signed informed consent form to
participate in this study.Immunohistochemistry
Tissue sections were stained with hematoxylin-eosin and
reevaluated by an independent pathologist to conﬁrm the
OSCC diagnosis. Parafﬁn sections (5 mm thick) were
used for immunostaining of Shp2 protein. In brief, the
sections were heated for 30 minutes at 68C and then
deparafﬁnized in xylene 3 times for 10 minutes each and
rehydrated in a series of graded ethanol (100% to 50%
ethanol and then in distilled water). Sections were
incubated for 10 minutes in 3% H2O2 in phosphate
buffered saline (PBS) and with normal serum for
30 minutes. A monoclonal anti-Shp2 antibody (Y478;
Abcam, Cambridge, MA, USA) was applied to the
sections at a dilution of 1:50 and incubated overnight at
4C. On the next day, the sections were further incubated
at room temperature for 1 hour and then incubated with a
secondary antibody for 30 minutes. After the specimens
were washed 3 times for 5 minutes each with PBS, the
bound primary antibody was visualized by incubating
the sections for 5 seconds in diaminobenzidine tetrahy-
drochloride solution (Sigma-Aldrich, St Louis, MO,
USA). The sections were rinsed in distilled water for 5
minutes, counterstained with Harris hematoxylin,
dehydrated, cleared, and mounted. Finally, the sections
were reviewed and scored by 2 pathologists who were
blinded to patients’ identiﬁcation and clinical data.
Normal and cancerous cells with an obvious membra-
nous or cytoplasmic staining were deﬁned as positive
staining. The percentages of positive staining (P) were
scored as 0 (<10%), 1 (10%-25%), 2 (26%-50%), 3
(51%-75%), and 4 (76%-100%), and the levels of in-
tensity of staining (I) were determined as 0, negative; 1,
light yellow (weak staining); 2, brown (moderate stain-
ing); and 3, dark brown (strong staining). The total
scores (S) were designated as P  I for each section.Cell line and culture
A specimen from a human tongue squamous cancer
cell line, SCC-4, was obtained from the Department
of Oral and Maxillofacial Surgery, The Ninth
People’s Hospital, Shanghai Jiao Tong University
School of Medicine, having been originally pur-
chased from ATCC, where it was characterized
by mycoplasma detection, DNA ﬁngerprinting,
isozyme detection, and cell vitality detection. The
cell line was refreshed every 3 to 4 months from a
frozen vial of the same batch of cells for this study.
Cells were cultured in high-glucose Dulbecco
modiﬁed Eagle medium (DMEM) containing 10%
fetal bovine serum with 100 U/mL penicillin and
100 mg/mL streptomycin at 37C in 5% CO2.
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shRNA and gene transfection
To knock down Shp2 expression in cell lines, we ﬁrst
designed and synthesized Shp2 shRNAs according
to Shp2 cDNA sequences (Gen-Bank accession
NM_002834) from Shanghai Genomeditech Co Ltd
(Shanghai, China). Shp2 shRNA1 sequences were
50-GTAACCCTGGAGACTTCAC-30, shRNA 2, 50-
GATTCAGAACACTGGTGAT-30; and shRNA3, 50-
CGCTAAGAGAACTTAAACTTT-30. The sequence
50-TTCTCCGAACGTGTCACGT-30, which had no
signiﬁcant homology to any known human or mouse
genes, was used as a negative control. These oligonu-
cleotides were then subcloned into a lentiviral vector
(pGMLV-SB1 RNAi; Shanghai Genomeditech Co Ltd,
Shanghai, China), and the lentiviruses were produced in
293T cells. After estimating multiplicity of infection
using a standard procedure, the authors used these vi-
ruses to infect SCC-4 cells using an Oligofectamine
transfection reagent (Invitrogen, Carlsbad, CA, USA).
Cells were divided into 3 groups, control (infection
with PBS alone), mock (infection with negative control
lentiviral vector), and Shp2-RNAi (Shp2-shRNA1, 2,
or 3 lentiviral vector). They were subcultured at a
density of 2  105 cells per well into 6-well cell culture
plates. After 48 hours of culture, the cells were infected
with Shp2 shRNA1, 2, and 3 or a negative control
lentiviral vector at a multiplicity of infection of 1.5
according to the pre-experimental data. Thereafter, the
cells were observed under a ﬂuorescence microscope
and harvested on the 4th, 7th, and 10th days after
infection. Shp2 knockdown was conﬁrmed by real-time
polymerase chain reaction (PCR) and Western blot.Real-time reverse transcription PCR
After infection with lentivirus for 4 days, real-time PCR
was performed to detect expression of Shp2 mRNA
in a human tongue squamous cancer cell line using
the PrimeScript RT reagent kit (Takara, Japan) accord-
ing to the manufacturer’s instructions. Shp2 primers
were 50-GACTTTTGGCGGATGGTGTTCC-30 and 50-
CGGCGCTTTCTTTGACGTTCCT-30. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) primers were 50-
GTCTCCTCTGACTTCAACAGCG-30 and 50-ACCAC-
CCTGTTGCTGTAGCCAA-30, which was used as an
internal control for standardization. All PCR ampliﬁca-
tions were performed in triplicate and repeated once. Data
were analyzed using the comparative Ct method.Protein extraction and Western blot
Total cellular protein from tissues and cells was
extracted using an immunoprecipitation lysis buffer
containing 50mM Tris-Cl (pH 7.5), 150mM NaCl,
10mM MgCl2, 1mM ethylene diamine-tetracetate(pH 8.0), 1% Nonidet P-40, 100mM sodium ﬂuoride,
1mM phenylmethylenesulfonylﬂuoride, and 2 mL/mL
protease inhibitor cocktail (Sigma-Aldrich, St Louis,
MO, USA). The protein concentration was determined
by the BCA method (Pierce, Rockford, USA). Protein
samples of 40 mg were separated by sodium dodecyl
sulfateepolyacrylamide gel electrophoresis and elec-
trophoretically transferred onto polyvinylidene
diﬂuoride membranes (Invitrogen, Carlsbad, CA).
After blocking with 5% nonfat milk in Tris-buffered
saline containing 0.05% Tween-20 (TBST) for 1 hour
at room temperature, the membranes were incubated
with anti-Shp2 (Y478; Abcam), anti-p53, Bax, Bcl-2,
or b-actin (all from Santa Cruz Biotechnology, Santa
Cruz, CA, USA) overnight at 4C. The membranes
were then washed with TBST thrice and further incu-
bated with horseradish peroxidase-conjugated anti-
rabbit immunoglobulin G (Cell Signaling Technology,
Beverly, MA, USA) secondary antibody for 1 hour at
37C, and protein bands were visualized by using an
enhanced chemiluminescence kit (Millipore, Bedford,
MA, USA).
Cell viability MTT assay
SCC-4 cells were inoculated into a 96-well plate with
100 mL medium at a density of 5  103 cells per well.
At 24 hours, 48 hours, 72 hours, and 96 hours after
lentivirus infection, 20 mL MTT (5 mg/mL) solution
was added to each well and incubated for 4 hours at
37C. The medium was then discarded, and 150 mL
dimethyl sulfoxide was added and oscillated. Optical
density (OD) at a wavelength of 492 nm was read by
enzyme-labeled analyzer (Labsystems Dragon Well-
scan MK3, Finland). Cell viability was calculated by
the following formula: % of control ¼ (1  OD value
of the experimental group/OD value of the control
group)  100.
Flow cytometric apoptosis assay
Cells were collected after lentivirus infection for
72 hours, washed twice with PBS, and then resus-
pended with 100 mL prechilled 1 binding buffer from
an Annexin V-APC/7-AAD kit (Becton Dickinson,
San Jose, CA, USA). The cell density was adjusted to
1  106/mL, and then 5 mL PE Annexin V and 5 mL 7-
ADD were added into cell solutions and incubated in
the dark for 30 minutes. Afterward, 400 mL of 1
binding buffer was added and mixed thoroughly. The
apoptotic rate was detected by ﬂow cytometer (Becton
Dickinson, San Jose, CA, USA).
Tumor cell Transwell invasion assay
Upper and lower Transwell chambers were separated
by a polycarbonate membrane with 8 mm pores. The
Fig. 1. Western blot analysis of Shp2 protein expression in
OSCC tissues (T) and distant nonmalignant tissues (N).
(OSCC, oral squamous cell carcinoma.)
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(30 mL per chamber) and gelled at 37C for 4 hours.
The postinfected cells were added into the upper
chamber at a density of 2  104 cells in serum-free
medium, and the lower chamber was ﬁlled with 600 mL
DMEM containing 10% fetal calf serum. The Transwell
inserts were then incubated for 24 hours; at the end of
experiments, cells on the upper side of the insert ﬁlter
were removed with a cotton bud, and the cells invading
the opposite side of the membrane were stained using
0.1% crystal violet for 30 minutes. Five visual ﬁelds
were randomly selected and the number of cells coun-
ted under an inverted microscope. The experiment was
repeated 3 times.Statistical analysis
Data were expressed as mean  standard deviation. All
statistical analyses were carried out using SPSS soft-
ware, Version 11.0 (SPSS Inc, Chicago, IL, USA).
Comparisons between the relative expression value of
Shp2 or the intensity of its expression in OSCC and
adjacent epithelium were analyzed using a Wilcoxon
nonparametric test. The Mann-Whitney U test was used
for 2eindependent sample analyses (such as comparison
of Shp2 expression intensity in OSCC regarding gender,
age, tobacco smoking, alcohol consumption, N stage,
and clinical stage), whereas the Wilcoxon test was used
to assess the paired samples (such as comparison be-
tween Shp2 expression intensity in OSCC and adjacent
epithelium). Furthermore, the Kruskal-Wallis test was
used to compare more than 2 samples that were inde-
pendent or not related (such as comparison of Shp2
expression intensity in OSCC regarding T stage and
pathologic differentiation grade). Other statistical com-
parisons were analyzed using t test and 1-way analysis of
variance followed by the Tukey HSD (honestly signiﬁ-
cant difference) post hoc test. Differences were consid-
ered statistically signiﬁcant at P < .05.RESULTS
Upregulation of Shp2 protein in OSCC tissues and
cell lines
In this study, we ﬁrst assessed Shp2 expression in
OSCC tissue samples. We found that expression of
Shp2 protein was higher in OSCC tissue than in the
adjacent nontumor tissue, except in 1 sample (Figure 1).
Shp2 protein was mainly localized in the cytoplasm
(Figure 2). Of these 70 cases, 46 cases had OSCC tis-
sues and the corresponding adjacent normal epithelium
in the same section. In the adjacent normal epithelium,
Shp2 protein was either absent or weakly expressed,
whereas the average total score of Shp2 protein levels
in OSCC tissues was signiﬁcantly higher than that in
adjacent normal epithelium (P ¼ .031; Table I).Association of Shp2 expression with
clinicopathologic data from patients
Table II summarized the parameters of 70 patients with
OSCC. Speciﬁcally, there was no signiﬁcant association
between Shp2 expression and patient age (P¼ .738), sex
(P ¼ .773), tobacco smoking (P ¼ .773), alcohol
drinking (P ¼ .211), tumor size (P ¼ .189), anatomical
location (P¼ .811), tumor stage (P¼ .109), or histologic
grade (P ¼ .094; Figure 2, B, C, D). In contrast, there
was signiﬁcant association of Shp2 expression with tu-
mor clinical stage (P ¼ .003; Figure 2, G, H) and lymph
node metastasis (P ¼ .010; Figure 2, E, F).Effect of Shp2 silence on regulation of OSCC cell
viability, apoptosis, and invasion capacity
After the steps outlined earlier, we produced lentiviruses
carrying Shp2 shRNA to knock down Shp2 expression
in OSCC cells. We ﬁrst assessed the infection rate by
determining the expression rate of lentiviruses carrying
GFP (green ﬂuorescent protein) under a ﬂuorescent
microscope 96 hours after infection and found that the
infection efﬁciency of lentivirus vs the negative control
(mock) in SCC-4 cells was more than 90% (data not
shown). Real-time PCR data indicated that levels of
Shp2 expression in Shp2 shRNA1, 2, and 3 subgroups
were reduced by 39%, 47%, and 75%, respectively
(Figure 3, A). Western blot analysis conﬁrmed that the
levels of Shp2 protein expression in these 3 subgroups
were also signiﬁcantly reduced (Figure 3, B).
The effect of Shp2 knockdown on regulation of SCC-
4 cell viability was determined by using MTT assay. As
shown in Figure 4, A, SCC-4/Shp2, Shp2 shRNA3
lentivirus-infected cells had a reduction in cell viability
compared with control cells. Annexin V/7-ADD staining
showed that the reduced cell viability was due to in-
duction of apoptosis (P < .05; see Figure 4, B, C).
Moreover, knockdown of Shp2 expression on SCC-4
cells signiﬁcantly reduced tumor cell invasive capacity
compared with control cells (P < .05; Figure 4, D).Effect of Shp2 silence on regulation of apoptosis-
related protein expression
We assessed expression of pro-apoptotic proteins after
Shp2 knockdown and found that expression of p53
Fig. 2. Immunohistochemical detection of Shp2 expression in OSCC and normal tissues (diaminobenzidine tetrahydrochloride,
brown color). A, Immunohistochemical staining of Shp2 in a section with both normal epithelium and OSCC tissue (original
magniﬁcation 100). A0, staining in the adjacent normal epithelium (magniﬁcation of the box). A00, staining in the OSCC
(magniﬁcation of the box). B, Poorly differentiated OSCC tissue. C, Moderately differentiated OSCC tissue. D, Well-differentiated
OSCC tissue. E, Primary tumor of OSCC without lymph node metastasis. F, Primary tumor of OSCC with lymph node metastasis.
G, OSCC-early stage (T2N0M0). H, OSCC-advanced stage (T4N0M0) (original magniﬁcation 200). (OSCC, oral squamous cell
carcinoma.)
Table I. Differential expression of Shp2 protein in
paired tumor vs normal tissues (n ¼ 46)
Cases
Total scores (mean 
standard deviation) P
Adjacent non-
malignant epithelium
46 2.43  1.58 .031
Cancerous tissue 46 4.82  2.52
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cells (Figure 5). Meanwhile, Shp2 knockdown was able
to induce an increase in expression of Bax protein but
decreased expression of bcl-2 protein (Figure 5).DISCUSSION
In this study, we ﬁrst detected Shp2 expression in
OSCC tissue samples and found that Shp2 was upre-
gulated in tumor tissue vs the adjacent normal or distant
normal tissue. Upregulated Shp2 expression was asso-
ciated with advanced tumor clinical stage and lymph
node metastasis. Knockdown of Shp2 expression in
vitro inhibited OSCC cell viability and invasion, but
induced OSCC cells to undergo apoptosis. Knockdown
of Shp2 expression also modulated expression of p53,
Bax, and Blc-2 proteins in OSCC cells. These data
indicated that Shp2 expression was associated with
OSCC progression ex vivo. The in vitro study found
that knockdown of Shp2 expression could inhibit tumor
cell viability and invasion but induce tumor cell
apoptosis. Overall, these data suggested that PTPN11may act as an oncogene in OSCC and should be further
evaluated as a biomarker for prediction of tumor pro-
gression and as a novel therapeutic target for OSCC.
PTPN11 plays a regulatory role in various cells
that is important for diverse cell functions, such as
mitogenic activation, metabolic control, transcription
regulation, and cell migration.11-15 Regarding tumori-
genesis, Shp2 was ﬁrst identiﬁed as a proto-oncogene
because activating mutations of the PTPN11 gene are
associated with leukemogenesis.29 However, it has
been found in recent studies that Shp2 acts as a tumor
suppressor in hepatocarcinogenesis.25,26 In this study,
our data indicated that the expression of Shp2 protein
was upregulated in OSCC and associated with
advanced tumor clinical stage and lymph node metas-
tasis, supporting the observation that Shp2 is a proto-
oncogene in OSCC. In this study, our patients did not
have any distant metastasis, even in patients with stage
IV disease. Thus, we were not able to evaluate the as-
sociation of Shp2 expression with tumor distant
metastasis. This ﬁnding was consistent with those of
previous studies examining other tumors.18-23,30 For
example, Zhou et al.30 found that Shp2 protein was
signiﬁcantly elevated in breast cancer and associated
with tumor lymph node metastasis, nuclear accumula-
tion of hormone receptor, and higher tumor grade,
suggesting that Shp2 may play a principal role in
regulation of invasion and metastasis. Moreover, in-
crease in tumor cell immunogenicity could inhibit tu-
mor growth and metastasis.31,32 Recently, Leibowitz
et al.33 found that Shp2 was overexpressed in head and
Table II. Association of Shp2 expression with clinicopathologic characteristics of OSCC (n ¼ 70)
Classiﬁcation Cases
Cancerous protein positive
grade (mean  standard
deviation)
Nonparametric
test P
Age (y)
<60 27 4.66  2.23 Z ¼ 0.335 .738
60 43 4.60  2.61
Gender
Female 29 4.65  2.81 Z ¼ 0.289 .773
Male 41 4.60  2.21
Smoking
Yes 50 4.64  2.52 Z ¼ 0.341 .733
No 20 4.60  2.37
Drinking
Yes 42 4.91  2.56 Z ¼ 1.250 .211
No 28 4.17  2.27
Tumor size
<31 mm 32 4.48  2.41 Z ¼ 1.312 .189
31 mm 38 1.54  0.50
Anatomic locations
Tongue 26 5.03  2.04 c2 ¼ 0.651
df ¼ 5
.986
Gingiva 17 4.76  2.75
Mouth ﬂoor 8 5.00  1.77
Lip 7 4.71  2.05
Cheek 8 4.75  1.83
Soft palate 4 4.50  2.51
T stage
T1 24 3.70  1.73 c2 ¼ 4.439
df ¼ 2
.109
T2 38 5.10  2.67
T3 8 5.12  2.74
N stage
N0 36 4.02  2.47 Z ¼ 2.572 .010*
N1-N2 34 5.26  2.31
Clinical stage
Stage I/II 41 4.02  2.39 Z ¼ 2.940 .003*
Stage III/IV 29 5.48  2.33
Pathologic differentiation grade
Well 30 4.60  2.64 c2 ¼ 4.719
df ¼ 2
.094
Moderately 36 4.86  2.38
Poorly 4 2.75  0.50
Cancerous protein positive grade indicated the average score of immunohistochemical staining. The various nonparametric test values were
calculated with SPSS software, version 11.0 (SPSS Inc).
OSCC, oral squamous cell carcinoma.
*P < .05.
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pression of pSTAT1 and consequent antigen processing
machinery component-mediated immune escape in
head and neck cancer cells from cytotoxic T lympho-
cytes recognition. Taken together, Shp2 expression
should be further evaluated as a novel biomarker for
early detection and as a predictor of OSCC progression.
You et al.34 indicated that Shp2 was able to promote
cell growth and survival. Activation of growth fac-
toreinitiated mitogenic pathways and suppression of
cytotoxic effect induced by interferon were involved in
mechanistic pathways. However, there are many un-
knowns about the Shp2 functions in OSCC. In the past
few years, shRNA has been widely used to knock down
expression of many genes because of its high speciﬁcityand apparent low toxicity.35-37 In the current study, we
produced lentivirus carrying Shp2 shRNA and knocked
down Shp2 expression in OSCC cells. Our in vitro
data further supported our ex vivo data, showing that
knockdown of Shp2 expression reduced OSCC cell
viability and invasion capacity but induced apoptosis.
Apoptosis exerts a negative regulatory function in cancer
development and progression by eliminating the rapid
growth of tumor cells. However, a decrease in tumor cell
apoptosis or arrest of the cell cycle accumulates a large
number of abnormal cells and induces tumor progression
and metastasis.38 Tumor invasion and metastasis are
characteristic features of OSCC, and those factors are
important in the prognosis of OSCC patients.39 The
present study found that invasive capability of SCC-4
Fig. 4. Effects of Shp2 knockdown on regulation of OSCC cell viability, apoptosis, and invasion capacity in vitro. A, Cell viability
MTT assay. B, Flow cytometric apoptosis assay. C, Summarized data for apoptosis assay (*P < .05). D, Tumor cell invasion assay
(*P < .05). (OSCC, oral squamous cell carcinoma.)
Fig. 3. Knockdown of Shp2 expression in SCC-4 cells after infection with lentivirus carrying Shp2 shRNAs. A, qRT-PCR. B,
Western blot. SCC-4 cells were grown and infected with or without lentivirus carrying Shp2 shRNA or negative control shRNA for
4 days and then subjected to qRT-PCR and Western blot analyses. (Con, control; Mock, SCC-4 transfected with negative control
lentivirus; SCC-4, a cell line; qRT-PCR, real-time reverse-transcription quantitative polymerase chain reaction.)
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Agazie18 also reported that inhibition of Shp2 could
suppress epidermal growth factoreinduced activation of
the Ras-ERK and the PI3K-Akt signaling pathways, and
induce reversion to a normal breast epithelial phenotype,
which may be relevant to cell migration and malignant
transformation. We speculate that the effect of Shp2 on
OSCC cells could be attributed to 2 aspects, (1) upre-
gulated expression of Shp2 protein could inhibit apo-
ptosis that appeared to be responsible for reduction of
cell death, and (2) Shp2 might downregulate expression
of certain cell adhesion molecules to induce cell migra-
tion and invasion.40,41 Future studies will investigate the
possibility and feasibility of targeting Shp2 as a novel
anticancer strategy in OSCC.
In addition, the present study also found that Shp2
knockdown regulated expression of apoptosis-related
genes. Indeed, p53 can promote apoptosis throughthe mitochondrial pathway that shifts the balance of
bcl-2 family proteins toward the pro-apoptotic mem-
bers and induces caspase-mediated apoptosis. The
altered bax/bcl-2 ratio could result in signiﬁcant acti-
vation of caspases and apoptosis.42 Recent studies
found that Shp2 was a negative regulator of the Jak/
STAT pathway that regulates cell proliferation, differ-
entiation, and apoptosis.34 Moreover, Leibowitz et al.33
described the role of Shp2 in the immune escape of
head and neck cancer cells from cytotoxic T lympho-
cyte recognition.
In summary, the results presented in this study
indicate that Shp2 may be an oncogene and promote
OSCC lymph node metastasis. These data also suggest
that Shp2 might be further evaluated as a biomarker for
prediction of OSCC progression and that targeting of
Shp2 may provide a novel therapeutic strategy for
clinical control of OSCC in the future.
Fig. 5. Effect of Shp2 knockdown on regulation of apoptosis-
related gene expressions. The cells were grown and infected
with Shp2 shRNA3 for 72 hours and subjected to Western
blot analysis of p53, Bax, and bcl-2 expression in SCC-4
cells. (SCC-4, a cell line.)
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